Helicobacter pylori: tailored therapy with novel sequential quadruple therapies (Q42774068)

7 November 2017

Helicobacter pylori: tailored therapy with novel sequential quadruple therapies (English)

1 reference

7 November 2017

1 reference

2

1 reference

7 November 2017

1

David Y Graham

1 reference

7 November 2017

PMCID

3873761

language of work or name

English

0 references

publication date

27 November 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

7 November 2017

1 reference

7 November 2017

10

1 reference

7 November 2017

1

1 reference

7 November 2017

6-8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2012.232

7 November 2017

0 references

cites work

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Optimal therapy for Helicobacter pylori infections

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3873761

Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection

16 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.232

10.1038/NRGASTRO.2012.232

31 March 2020

Identifiers

DOI

1 reference

7 November 2017

1 reference

7 November 2017

1 reference

PMCID

3873761